Viromed Medical AGFRA:VME +0.74%22 PB Ratio is 13.79 as of Jul. 03, 2026, which is 62% above its 10-year median of 8.52. GuruFocus rates FRA:VME with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Viromed Medical AG ranks worse than 94.54% on this metric.
Viromed Medical AG stock PB Ratio (=13.79) is close to 2-year high of 15.01.
The historical rank and industry rank for Viromed Medical AG's PB Ratio or its related term are showing as below:
FRA:VME'
s PB Ratio Range Over the Past 10 Years
Min: 3.65 Med: 8.52 Max: 15.01
Current: 13.79
During the past 5 years, Viromed Medical AG's highest PB Ratio was 15.01. The lowest was 3.65. And the median was 8.52.
FRA:VME's PB Ratio is ranked worse than 94.54% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs FRA:VME: 13.79
During the past 12 months, Viromed Medical AG's average Book Value Per Share Growth Rate was 7.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -20.80% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Viromed Medical AG was 236.70% per year. The lowest was -20.80% per year. And the median was 107.95% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Viromed Medical AG PB Ratio Related Terms
Viromed Medical AG PB Ratio Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Viromed Medical AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Viromed Medical AG (FRA:VME) has a PB Ratio of 13.79 as of Jul. 03, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Viromed Medical AG and its competitors. This is 62% above median its historical median of 8.52. Over the past decade, Viromed Medical AG's PB Ratio has ranged from 3.65 to 15.01. According to the industry distribution chart, Viromed Medical AG ranks #744 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 94.5%.
Is Viromed Medical AG's PB Ratio too high?
Viromed Medical AG's current PB Ratio of 13.79 is 62% above median its 10-year median of 8.52. Over the past 10 years, this metric has ranged from a low of 3.65 to a high of 15.01. The Medical Devices & Instruments industry median PB Ratio is 2.09. Viromed Medical AG's value of 13.79 is 559.8% above this industry median. Based on the distribution chart, Viromed Medical AG ranks #744 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #744 out of 787 companies for PB Ratio. This places Viromed Medical AG in the lower half of its industry. The industry median PB Ratio is 2.09. Viromed Medical AG's value of 13.79 is 559.8% above this benchmark. Historically, Viromed Medical AG's own PB Ratio has ranged from 3.65 to 15.01 over the past decade. While the company's 10-year median is 8.52 vs. the industry median of 2.09, Viromed Medical AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.09, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viromed Medical AG's current PB Ratio of 13.79 is 559.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current PB Ratio is 13.79, which is 62% above median its own 10-year median of 8.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (FRA:VME) has a current PB Ratio of 13.79. The current PB Ratio is 13.79, which is 62% above median its 10-year median of 8.52 and 559.8% above the Medical Devices & Instruments industry median of 2.09. Viromed Medical AG's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Viromed Medical AG (FRA:VME), the current PB Ratio is 13.79 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score
Get the complete analysis for FRA:VME
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VME has been successfully added to your 
